REFERENCES
1. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int 2018;2018:5416923.
3. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 2008;35:S1-S14. Quiz S39
4. Kane SE. Multidrug resistance of cancer cells. In: Testa B, Meyer U, editors. Advances in Drug Research vol.28. New York: Academic Press; 1996. pp. 181-252.
5. Mitscher LA, Pillai SP, Gentry EJ, Shankel DM. Multiple drug resistance. Med Res Rev 1999;19:477-96.
7. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-726.
8. Kartal-Yandim M, Adan-Gokbulut A, Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol 2016;36:716-26.
10. Raz S, Sheban D, Gonen N, Stark M, Berman B, et al. Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest. Cell Death Dis 2014;5:e1067.
11. Zhou X, Li D, Wang X, Zhang B, Zhu H, et al. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Oncotarget 2015;6:3111-22.
12. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996;1288:F37-54.
13. Hrycyna CA, Gottesman MM. Multidrug ABC transporters from bacteria to man: an emerging hypothesis for the universality of molecular mechanism and function. Drug Resist Updat 1998;1:81-3.
14. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
15. Chen Z, Shi T, Zhang L, Zhu P, Deng M, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett 2016;370:153-64.
16. El-Awady R, Saleh E, Hashim A, Soliman N, Dallah A, et al. The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy. Front Pharmacol 2017;7:535.
17. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
18. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009;14:3-9.
19. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
20. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
21. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77.
22. Tarling EJ, de Aguiar Vallim TQ, Edwards PA. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol Metab 2013;24:342-50.
23. Cant N, Pollock N, Ford RC. CFTR structure and cystic fibrosis. Int J Biochem Cell Biol 2014;52:15-25.
24. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
25. Rosenberg MF, Callaghan R, Ford RC, Higgins CF. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 1997;272:10685-94.
26. Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change in strategy? Drug Metab Dispos 2014;42:623-631.
27. Müller M, de Vries EG, Jansen PL. Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells. J Hepatol 1996;24:100-8.
28. Baiceanu E, Nguyen KA, Gonzalez-Lobato L, Nasr R, Baubichon-Cortay H, et al. 2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2. Eur J Med Chem 2016;122:408-18.
29. Lage H, Dietel M. Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 2000;1:169-75.
30. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001;280:1216-23.
31. Horsey AJ, Cox MH, Sarwat S, Kerr ID. The multidrug transporter ABCG2: still more questions than answers. Biochem Soc Trans 2016;44:824-30.
32. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003;278:8294-9.
33. Wu Yj, Wang C, Wei W. The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases. Biomed Pharmacother 2018;105:870-8.
35. Senior AE, al-Shawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. FEBS Lett 1995;377:285-9.
36. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11:918-26.
37. Siarheyeva A, Liu R, Sharom FJ. Characterization of an asymmetric occluded state of P-glycoprotein with two bound nucleotides: implications for catalysis. J Biol Chem 2010;285:7575-86.
38. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006;443:180-5.
39. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc Natl Acad Sci U S A 2007;104:19005-10.
41. Li J, Jaimes KF, Aller SG. Refined structures of mouse P-glycoprotein. Protein Sci 2014;23:34-46.
42. Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol 2014;54:95-117.
43. Abele R, Tampé R. Peptide trafficking and translocation across membranes in cellular signaling and self-defense strategies. Curr Opin Cell Biol 2009;21:508-15.
44. Loo TW, Clarke DM. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. J Biol Chem 2000;275:5253-6.
45. Pinkett HW, Lee AT, Lum P, Locher KP, Rees DC. An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science 2007;315:373-7.
46. Bolhuis H, van Veen HW, Molenaar D, Poolman B, Driessen AJ, et al. Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. EMBO J 1996;15:4239-45.
48. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
49. Jones PM, George AM. A new structural model for P-glycoprotein. J Membr Biol 1998;166:133-147.
50. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003;52:759-66.
51. Loo TW, Clarke DM. Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein. Biochem Cell Biol 1999;77:11-23.
52. Jones PM, George AM. Symmetry and structure in P-glycoprotein and ABC transporters what goes around comes around. Eur J Biochem 2000;267:5298-305.
53. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
54. Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014;20:793-807.
55. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006;25:231-59.
56. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-27.
57. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
58. Cole SP, Deeley RG. Multidrug resistance-associated protein: sequence correction. Science 1993;260:879.
59. McGrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988;48:3959-63.
60. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-10.
61. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006;580:2903-9.
62. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997;57:5232-7.
63. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Müller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 1999;126:681-8.
64. Ween MP, Armstrong MA, Oehler MK, Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol 2015;96:220-56.
65. Krizkova V, Dubova M, Susova S, Vycital O, Bruha J, et al. Protein expression of ATP-Binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients. Cancer Chemother Pharmacol 2016;78:595-603.
66. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
67. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59:8-13.
68. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002;97:626-30.
69. Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008;4:1-15.
70. Wang H, Lee EW, Cai X, Ni Z, Zhou L, et al. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry 2008;47:13778-87.
71. Wong K, Briddon SJ, Holliday ND, Kerr ID. Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques. Biochim Biophys Acta 2016;1863:19-29.
72. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 2012;31:73-99.
73. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56.
74. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, et al. Association of high-level MRPl expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-53.
75. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005;128:324-32.
76. Suvannasankha A, Minderman H, O’Loughlin KL, Nakanishi T, Ford LA, et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 2004;127:392-8.
77. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004;10:1691-7.
78. Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006;91:825-8.
79. Li W, Zhang H, Assaraf YG, Zhao K, Xu X, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat 2016;27:14-29.
80. Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 2015;18:1-17.
82. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
83. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
84. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012;19:1946-2025.
85. Waghray D, Zhang Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem 2018;61:5108-21.
86. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995;13:1985-94.
87. Minderman H, O’Loughlin KL, Pendyala L, Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 2004;10:1826-34.
88. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000;18:1837-44.
89. Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008;26:2674-82.
90. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413-21.
91. Luurtsema G, Schuit RC, Klok RP, Verbeek J, Leysen JE, et al. Evaluation of [11C.laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol 2009;36:643-9.
92. Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs 2005;23:311-5.
93. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004;53:173-8.
94. Dörner B, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, et al. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem 2009;52:6073-82.
95. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447-59.
96. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 2002;27:119-26.
97. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-91.
98. Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab 2011;12:722-31.
99. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. Methods Mol Biol 2010;596:341-58.
100. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010;116:4077-85.
101. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17:569-80.
102. Karthikeyan S, Hoti SL. Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance. Anticancer Agents Med Chem 2015;15:605-15.
103. Ceballos MP, Rigalli JP, Cere LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem 2018;25:1-26.
104. Ginwala R, Bhavsar R, Chigbu DI, Jain P, Khan ZK. Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin. Antioxidants (Basel) 2019;8:pii:E35.
105. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006;78:2116-30.
106. Peña-Solórzano D, Stark SA, König B, Sierra CA, Ochoa-Puentes C. ABCG2/BCRP: Specific and Nonspecific Modulators. Med Res Rev 2017;37:987-1050.
107. Kiemlian Kwee J. Yin and Yang of Polyphenols in Cancer Prevention: A Short Review. Anticancer Agents Med Chem 2016;16:832-40.
108. Pick A, Müller H, Mayer R, Haenisch B, Pajeva IK, et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 2011;19:2090-102.
109. Zhang S, Wang X, Sagawa K, Morris ME. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos 2005;33:341-8.
110. Yuan J, Wong IL, Jiang T, Wang SW, Liu T, et al. Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. Eur J Med Chem 2012;54:413-22.
111. Ahmed-Belkacem A, Pozza A, Macalou S, Pérez-Victoria JM, Boumendjel A, et al. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anticancer Drugs 2006;17:239-43.
112. Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004;64:4346-52.
113. An G, Morris ME. Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharm Res 2010;27:1296-308.
114. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-16.
115. Hadjeri M, Barbier M, Ronot X, Mariotte AM, Boumendjel A, et al. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J Med Chem 2003;46:2125-31.
116. Juvale K, Stefan K, Wiese M. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. Eur J Med Chem 2013;67:115-26.
117. Gallus J, Juvale K, Wiese M. Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta 2014;1838:2929-38.
118. Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, et al. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem 2012;55:966-70.
119. Winter E, Lecerf-Schmidt F, Gozzi G, Peres B, Lightbody M, et al. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2. J Med Chem 2013;56:9849-60.
120. Pires ADRA, Lecerf-Schmidt F, Guragossian N, Pazinato J, Gozzi GJ, et al. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2. Eur J Med Chem 2016;122:291-301.
121. van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett 2001;11:29-32.
122. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-25.
123. Han Y, Riwanto M, Go ML, Ee PL. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Eur J Pharm Sci 2008;35:30-41.
124. Boumendjel A, McLeer-Florin A, Champelovier P, Allegro D, Muhammad D, et al. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer 2009;9:242.
125. Juvale K, Pape VF, Wiese M. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg Med Chem 2012;20:346-55.
126. Valdameri G, Gauthier C, Terreux R, Kachadourian R, Day BJ, et al. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem 2012;55:3193-200.
127. Winter E, Devantier Neuenfeldt P, Chiaradia-Delatorre LD, Gauthier C, Yunes RA, et al. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones. J Med Chem 2014;57:2930-41.
128. Winter E, Gozzi GJ, Chiaradia-Delatorre LD, Daflon-Yunes N, Terreux R, et al. Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position. Drug Des Devel Ther 2014;8:609-19.
129. Kraege S, Stefan K, Juvale K, Ross T, Willmes T, et al. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2). Eur J Med Chem 2016;117:212-29.
130. Juvale K, Gallus J, Wiese M. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 2013;21:7858-73.
131. Stefan K. .
132. Kraege S, Köhler SC, Wiese M. Acryloylphenylcarboxamides: a new class of breast cancer resistance protein (ABCG2) modulators. ChemMedChem 2016;11:2422-35.
133. Kraege S, Stefan K, Köhler SC, Wiese M. Optimization of acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylates. ChemMedChem 2016;11:2547-58.
134. Silbermann K, Shah CP, Sahu NU, Juvale K, Stefan SM, et al. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2. Eur J Med Chem 2019;164:193-213.
135. Chang JB, Wang Q, Li YF. Synthesis and biological activity of Wuweizisu C and analogs. Curr Top Med Chem 2009;9:1660-75.
136. Jin J, Sun H, Wei H, Liu G. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis. Invest New Drugs 2007;25:95-105.
137. Gu X, Ren Z, Tang X, Peng H, Ma Y, et al. Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors. Bioorg Med Chem 2012;20:2540-8.
138. Gu X, Ren Z, Peng H, Peng S, Zhang Y. Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Biochem Biophys Res Commun 2014;455:318-22.
139. Gu X, Ren Z, Tang X, Peng H, Zhao Q, et al. Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors. Eur J Med Chem 2012;51:137-44.
140. Gu X, Tang X, Zhao Q, Peng H, Peng S, et al. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e.azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem Lett 2014;24:3419-21.
141. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002;64:573-82.
142. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 2004;68:2043-52.
143. Chearwae W, Shukla S, Limtrakul P, Ambudkar SV. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 2006;5:1995-2006.
144. Murakami M, Ohnuma S, Fukuda M, Chufan EE, Kudoh K, et al. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2. Drug Metab Dispos 2017;45:1166-77.
145. Pick A, Wiese M. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. ChemMedChem 2012;7:650-62.
146. Krapf MK, Wiese M. Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2). J Med Chem 2016;59:5449-61.
147. Krapf MK, Gallus J, Wiese M. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2). Eur J Med Chem 2017;139:587-611.
148. Krapf MK, Gallus J, Wiese M. 4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2). J Med Chem 2017;60:4474-95.
149. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 1999;9:595-600.
150. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403-11.
151. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104:682-91.
152. Pick A, Klinkhammer W, Wiese M. Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem 2010;5:1498-1505.
153. Pajeva IK, Wiese M. Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J 2009;11:435-44.
154. Marighetti F, Steggemann K, Hanl M, Wiese M. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors. ChemMedChem 2013;8:125-35.
155. Marighetti F, Steggemann K, Karbaum M, Wiese M. Scaffold identification of a new class of potent and selective BCRP inhibitors. ChemMedChem 2015;10:742-51.
156. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010;627:92-8.
157. Köhler SC, Wiese M. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). J Med Chem 2015;58:3910-21.
158. Köhler SC, Silbermann K, Wiese M. Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter. Eur J Med Chem 2016;124:881-95.
159. Köhler SC, Vahdati S, Scholz MS, Wiese M. Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors. Eur J Med Chem 2018;146:483-500.
160. Gujarati NA, Zeng L, Gupta P, Chen ZS, Korlipara VL. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. Bioorg Med Chem Lett 2017;27:4698-704.
161. Li XQ, Wang L, Lei Y, Hu T, Zhang FL, et al. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Eur J Med Chem 2015;101:560-72.
162. Gao Y, Shi W, Cui J, Liu C, Bi X, et al. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors. Bioorg Med Chem 2018;26:2420-7.
163. Peña-Solórzano D, Scholler M, Bernhardt G, Buschauer A, König B, et al. Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators. ACS Med Chem Lett 2018;9:854-9.
164. Teodori E, Dei S, Bartolucci G, Perrone MG, Manetti D, et al. Structure-Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers. ChemMedChem 2017;12:1369-79.
165. Li Y, Woo J, Chmielecki J, Xia CQ, Liao M, et al. Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. Bioorg Med Chem Lett 2016;26:551-5.
166. Liao M, Chuang BC, Zhu Q, Li Y, Guan E, et al. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP). Xenobiotica 2018;48:467-77.
167. Ma Y, Wink M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res 2010;24:146-9.
168. Spindler A, Stefan K, Wiese M. Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2). J Med Chem 2016;59:6121-35.
169. Ranjbar S, Firuzi O, Edraki N, Shahraki O, Saso L, et al. Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis. Medchemcomm 2017;8:1919-33.
170. Ranjbar S, Khonkarn R, Moreno A, Baubichon-Cortay H, Miri R, et al. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells. Toxicol Appl Pharmacol 2019;362:136-149.
171. Stefan K, Schmitt SM, Wiese M. 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein. J Med Chem 2017;60:8758-80.
172. Schmitt SM, Stefan K, Wiese M. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1). J Med Chem 2016;59:3018-33.
173. Wang S, Wan NC, Harrison J, Miller W, Chuckowree I, et al. Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance. J Med Chem 2004;47:1339-50.
174. Dantzic D, Noel P, Merien F3, Liu DX, Lu J, et al. The Effects of Synthetically Modified Natural Compounds on ABC Transporters. Pharmaceutics 2018;10:pii:E127.
175. Schäfer A, Köhler SC, Lohe M, Wiese M, Hiersemann M. Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators. J Org Chem 2017;82:10504-22.
176. Rho JR, Lee HS, Sim CJ, Shin J. Gagunins, highly oxygenated diterpenoids from the sponge Phorbas sp. Tetrahedron 2002;58:9585-91.
177. Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF. Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem 2007;2:1783-8.
178. Schwarz T, Montanari F, Cseke A, Wlcek K, Visvader L, et al. Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). ChemMedChem 2016;11:1380-94.
179. Kim BS, Lee K, Jung HJ, Bhattarai D, Kwon HJ. HIF-1 suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. Biochem Biophys Res Commun 2015;458:14-20.
180. Song JG, Lee YS, Park JA, Lee EH, Lim SJ, et al. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein. Cancer Chemother Pharmacol 2016;78:735-44.
181. Teodori E, Dei S, Floriddia E, Perrone MG, Manetti D, et al. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity. ChemMedChem 2015;10:1339-43.
182. Orlandi F, Coronnello M, Bellucci C, Dei S, Guandalini L, et al. New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). Bioorg Med Chem 2013;21:456-65.
183. Dei S, Braconi L, Trezza A, Menicatti M, Contino M, et al. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. Eur J Med Chem 2019;172:71-94.
184. Teodori E, Dei S, Garnier-Suillerot A, Gualtieri F, Manetti D, et al. Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. J Med Chem 2005;48:7426-36.
185. Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, et al. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J Med Chem 2010;53:1755-62.
186. Dei S, Coronnello M, Floriddia E, Bartolucci G, Bellucci C, et al. Multidrug Resistance (MDR) reversers: high activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. Eur J Med Chem 2014;87:398-412.
187. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001;299:620-8.
188. To KK, Poon DC, Wei Y, Wang F, Lin G, et al. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. Biochem Pharmacol 2015;97:27-37.
189. D'Cunha R, Bae S, Murry DJ, An G. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharm Drug Dispos 2016;37:397-408.
190. Fan YF, Zhang W, Zeng L, Lei ZN, Cai CY, et al. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett 2018;421:186-98.
